JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
NCT02848833 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3368
Last updated 2021-05-11
Summary
To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
JARDIANCE 10mg
T2DM with JARDIANCE 10mg
- DRUG
-
JARDIANCE 25mg
MT2DM with JARDIANCE 25mgax
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Boehringer Ingelheim · Boehringer Ingelheim
Eligibility
- Min Age
- 19 Years
- Max Age
- 110 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-08-10
- Primary Completion
- 2020-04-17
- Completion
- 2020-04-17
Countries
- South Korea
More Related Trials
-
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
NCT06308679 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
NCT03565458 ·Status: UNKNOWN ·Phase: PHASE1
-
Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States
NCT02857764 ·Status: COMPLETED
-
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
NCT07169981 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide
NCT02610088 ·Status: COMPLETED ·Phase: PHASE4
-
Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
NCT01001962 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
NCT06647888 ·Status: RECRUITING
-
24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
NCT02182830 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
NCT04203927 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
NCT05970237 ·Status: RECRUITING
-
SGLT2 Inhibition and Left Ventricular Mass
NCT02728453 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
NCT02413398 ·Status: COMPLETED ·Phase: PHASE3
-
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
NCT04937816 ·Status: COMPLETED
-
Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema
NCT02985242 ·Status: TERMINATED ·Phase: PHASE4
-
Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients
NCT02751398 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
NCT01164501 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Empagliflozin in NODAT
NCT03642184 ·Status: TERMINATED ·Phase: PHASE4
-
Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers
NCT06337409 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension
NCT06933355 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
NCT03667300 ·Status: COMPLETED ·Phase: PHASE2
-
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
NCT03492580 ·Status: COMPLETED
-
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
NCT06642272 ·Status: RECRUITING ·Phase: PHASE4
-
Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
NCT03764631 ·Status: COMPLETED
-
Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
NCT02998970 ·Status: UNKNOWN ·Phase: PHASE4
-
Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers
NCT06889350 ·Status: COMPLETED ·Phase: PHASE1